PolyPeptide Group AG (PPGN) - Total Assets
Based on the latest financial reports, PolyPeptide Group AG (PPGN) holds total assets worth CHF773.07 Million CHF (≈ $977.37 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See PPGN net asset value for net asset value and shareholders' equity analysis.
PolyPeptide Group AG - Total Assets Trend (2018–2024)
This chart illustrates how PolyPeptide Group AG's total assets have evolved over time, based on quarterly financial data.
PolyPeptide Group AG - Asset Composition Analysis
Current Asset Composition (December 2024)
PolyPeptide Group AG's total assets of CHF773.07 Million consist of 43.4% current assets and 56.6% non-current assets.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF68.28 Million | 9.0% |
| Accounts Receivable | CHF86.26 Million | 11.4% |
| Inventory | CHF146.35 Million | 19.3% |
| Property, Plant & Equipment | CHF388.99 Million | 51.4% |
| Intangible Assets | CHF15.02 Million | 2.0% |
| Goodwill | CHF0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how PolyPeptide Group AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PolyPeptide Group AG (PPGN) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PolyPeptide Group AG's current assets represent 43.4% of total assets in 2024, a decrease from 49.8% in 2018.
- Cash Position: Cash and equivalents constituted 9.0% of total assets in 2024, up from 3.5% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 3.0% in 2018.
- Asset Diversification: The largest asset category is property, plant & equipment at 51.4% of total assets.
PolyPeptide Group AG Competitors by Total Assets
Key competitors of PolyPeptide Group AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥16.53 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Shandong Lukang Pharmaceutical Co Ltd
SHG:600789
|
China | CN¥9.88 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
|
China | CN¥2.53 Billion |
PolyPeptide Group AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.62 | 1.59 | 2.21 |
| Quick Ratio | 0.82 | 0.72 | 1.08 |
| Cash Ratio | 0.39 | 0.26 | 0.00 |
| Working Capital | CHF122.90 Million | CHF109.03 Million | CHF19.33 Million |
PolyPeptide Group AG - Advanced Valuation Insights
This section examines the relationship between PolyPeptide Group AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.63 |
| Latest Market Cap to Assets Ratio | 1.07 |
| Asset Growth Rate (YoY) | 9.8% |
| Total Assets | CHF756.58 Million |
| Market Capitalization | $810.06 Million USD |
Valuation Analysis
Above Book Valuation: The market values PolyPeptide Group AG's assets above their book value (1.07x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: PolyPeptide Group AG's assets grew by 9.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for PolyPeptide Group AG (2018–2024)
The table below shows the annual total assets of PolyPeptide Group AG from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CHF756.58 Million ≈ $956.52 Million |
+9.79% |
| 2023-12-31 | CHF689.09 Million ≈ $871.19 Million |
+19.68% |
| 2022-12-31 | CHF575.78 Million ≈ $727.94 Million |
-3.24% |
| 2021-12-31 | CHF595.04 Million ≈ $752.29 Million |
+58.27% |
| 2020-12-31 | CHF375.98 Million ≈ $475.33 Million |
+23.21% |
| 2019-12-31 | CHF305.14 Million ≈ $385.78 Million |
+7.51% |
| 2018-12-31 | CHF283.83 Million ≈ $358.83 Million |
-- |
About PolyPeptide Group AG
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including t… Read more